Internationally Renowned Gynecologic Cancer Researcher Joins Ohio State  

Share this news item:

Contact Us

For media inquiries:
614-293-3737

To find a doctor, get a referral or for information on a clinical trial:
614-293-5066
or 800-293-5066

Search for a clinical trial

Posted: 1/6/2013

COLUMBUS, Ohio – Internationally renowned uterine cancer researcher and geneticist Paul Goodfellow will lead a new team of three researchers devoted to gynecologic oncology research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
 
“Paul’s expertise on the genetic and epigenetic events associated with the initiation and progression of uterine endometrial cancer makes him well-suited to lead this effort to accelerate gynecologic oncology research from basic science to Phase 1 clinical trials,” says Dr. Michael Caligiuri, director of Ohio State’s Comprehensive Cancer Center and CEO of The James.
 
“He is one of the latest high-level recruits that we have brought to Ohio State thanks to funds raised through Pelotonia,” says Caligiuri. “We are now capitalizing on the combined clinical and research expertise at Ohio State to devise better approaches to treating endometrial cancer and breast cancer, with the ultimate goal of bringing new treatments to patients sooner.”
 
Goodfellow comes to Ohio State from Washington University School of Medicine, where he was a professor of surgery, of genetics and of obstetrics and gynecology.
 
“As a geneticist, I’m interested in the genetics of tumor cells, and how gene changes influence how aggressively cancer cells will spread,” says Goodfellow, who has a doctorate of biology/pediatrics from Queen's University, Kingston, Canada. He also has a master’s of science in plant pathology from the University of Tennessee.
 
Throughout his career, Goodfellow’s research has made important contributions to improving women’s healthcare. He also has embraced his role in mentoring gynecologic oncologists in basic science and in translational research, helping to develop the next generation of physician scientists, including one of his former fellows, Dr. David Cohn, who is now director of the division of gynecologic oncology at Ohio State.
 
Goodfellow has a joint appointment within the division of gynecologic oncology of Ohio State’s Comprehensive Cancer Center and within the department of obstetrics and gynecology at Ohio State’s Wexner Medical Center.
While at the Siteman Cancer Center, Washington University School of Medicine, Goodfellow developed a prominent endometrial research group that focused on elucidating both the causes and consequences of defective DNA mismatch repair in endometrial cancer. The group’s translational research findings have significantly advanced knowledge about the most common gynecologic cancer.
 
In 2010, the Gynecologic Cancer Foundation (GCF) and the Claudia Cohen Research Foundation selected Goodfellow as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding Gynecologic Researcher. He also holds a leadership role in the national Gynecologic Oncology group that conducts national clinical trials for gynecologic cancers.
Each year more than 43,000 women are diagnosed with endometrial cancer and more than 7,700 die of the malignancy, according to the American Cancer Society.
 
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report. 
 
                                                                                 # # #
 
Click here for a high-quality photograph of Dr. Paul Goodfellow.
Click here for a video message from Dr. Paul Goodfellow.
 
Contact: Eileen Scahill, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu


Tags: Gynecologic Cancer; Gynecological Health; James Cancer Hospital

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu